Dr Reddy's Laboratories Ltd on Friday announced the launch of Trientine Hydrochloride capsules in the US market.
Trientine works by removing copper from the blood. It is used to treat Wilson's disease, a genetic metabolic defect that causes excess copper to build up in the body.
In a regulatory filing, Dr Reddy's Laboratories announced the launch of Trientine Hydrochloride capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine (trientine hydrochloride) capsules approved by the US Food and Drug Administration (USFDA).
"We are pleased to provide this convenient alternative for patients, pharmacists and distribution partners," Chief Executive Officer and Head of Dr Reddy's North America Generics Marc Kikuchi said.
The Syprine brand and generic products had US sales or approximately 94.2 million dollar MAT (Moving Annual Total) for the most recent twelve months ending in December 2019, according to IMS Health.
Dr Reddy's Trientine Hydrochloride capsules USP, 250 mg are available in 100 count bottles, the filing said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app